<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="102363"><DrugName>melatonin (neonatal sepsis/necrotizing enterocolitis/Smith-Magenis syndrome/short bowel syndrome/acetaminophen overdose/neonatal encephalopathy/perinatal asphyxia), Therapicon</DrugName><DrugNamesKey><Name id="43127989">Survivis</Name><Name id="43122917">Survivis 100</Name></DrugNamesKey><DrugSynonyms><Name><Value>melatonin</Value></Name><Name><Value>melatonin (neonatal sepsis/necrotizing enterocolitis/Smith-Magenis syndrome/short bowel syndrome/acetaminophen overdose/neonatal encephalopathy/perinatal asphyxia), Therapicon</Value></Name><Name><Value>Survivis 100</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Survivis</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>73-31-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20368">Therapicon Srl</CompanyOriginator><CompaniesPrimary><Company id="20368">Therapicon Srl</Company></CompaniesPrimary><CrossReferences><SourceEntity id="20368" type="Company"><TargetEntity id="5035527970" type="organizationId">Therapicon SRL</TargetEntity></SourceEntity><SourceEntity id="1023" type="ciIndication"><TargetEntity id="10061376" type="MEDDRA"/><TargetEntity id="D018883" type="MeSH"/></SourceEntity><SourceEntity id="114" type="ciIndication"><TargetEntity id="10040047" type="MEDDRA"/><TargetEntity id="D018805" type="MeSH"/><TargetEntity id="-200243460" type="omicsDisease"/><TargetEntity id="953" type="siCondition"/></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"/><TargetEntity id="88673" type="ORPHANET"/><TargetEntity id="-1116061312" type="omicsDisease"/><TargetEntity id="1973" type="siCondition"/></SourceEntity><SourceEntity id="2168" type="ciIndication"><TargetEntity id="10049416" type="MEDDRA"/><TargetEntity id="D012778" type="MeSH"/><TargetEntity id="104008" type="ORPHANET"/><TargetEntity id="-127143153" type="omicsDisease"/><TargetEntity id="403" type="siCondition"/></SourceEntity><SourceEntity id="2524" type="ciIndication"><TargetEntity id="R09.01" type="ICD10"/><TargetEntity id="799.01" type="ICD9"/><TargetEntity id="10003497" type="MEDDRA"/><TargetEntity id="D001237" type="MeSH"/><TargetEntity id="-353078630" type="omicsDisease"/><TargetEntity id="3123" type="siCondition"/></SourceEntity><SourceEntity id="315" type="ciIndication"><TargetEntity id="10008206" type="MEDDRA"/><TargetEntity id="D013345" type="MeSH"/><TargetEntity id="-1711474404" type="omicsDisease"/><TargetEntity id="329" type="siCondition"/></SourceEntity><SourceEntity id="367" type="ciIndication"><TargetEntity id="10063155" type="MEDDRA"/><TargetEntity id="D054508" type="MeSH"/><TargetEntity id="-1541096986" type="omicsDisease"/><TargetEntity id="1818" type="siCondition"/></SourceEntity><SourceEntity id="3798" type="ciIndication"><TargetEntity id="D020345" type="MeSH"/><TargetEntity id="-944362877" type="omicsDisease"/><TargetEntity id="3350" type="siCondition"/></SourceEntity><SourceEntity id="556" type="ciIndication"><TargetEntity id="10014625" type="MEDDRA"/><TargetEntity id="D001927" type="MeSH"/><TargetEntity id="-656163590" type="omicsDisease"/><TargetEntity id="881" type="siCondition"/></SourceEntity><SourceEntity id="609" type="ciIndication"><TargetEntity id="D030342" type="MeSH"/><TargetEntity id="-330405838" type="omicsDisease"/><TargetEntity id="1388" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="74" type="Action"><TargetEntity id="778" type="Mechanism">Antioxidants</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1023">Temperature disorder</Indication><Indication id="114">Sepsis</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="2168">Short bowel syndrome</Indication><Indication id="2524">Asphyxia</Indication><Indication id="315">Brain hemorrhage</Indication><Indication id="367">Radiation sickness</Indication><Indication id="3696">Paracetamol overdose</Indication><Indication id="3798">Necrotizing enterocolitis</Indication><Indication id="556">Brain disease</Indication><Indication id="609">Genetic disorder</Indication></IndicationsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="74">Antioxidant agent</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-14T12:12:07.000Z</LastModificationDate><ChangeDateLast>2019-05-13T00:00:00.000Z</ChangeDateLast><AddedDate>2016-06-08T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="20368" linkType="Company"&gt;Therapicon&lt;/ulink&gt; is investigating melatonin (Survivis 100, Survivis), an antioxidant,  for the potential treatment of neonatal sepsis, necrotizing enterocolitis, Smith-Magenis syndrome, short bowel syndrome, acetaminophen overdose, neonatal encephalopathy, perinatal asphyxia, subarachnoid hemorrhage, acute radiation syndrome, hepatocellular carcinoma, and heat stroke [&lt;ulink linkID="1768270" linkType="Reference"&gt;1768270&lt;/ulink&gt;], [&lt;ulink linkID="1769152" linkType="Reference"&gt;1769152&lt;/ulink&gt;],  [&lt;ulink linkID="1798089" linkType="Reference"&gt;1798089&lt;/ulink&gt;], [&lt;ulink linkID="1901651" linkType="Reference"&gt;1901651&lt;/ulink&gt;],  [&lt;ulink linkID="1906804" linkType="Reference"&gt;1906804&lt;/ulink&gt;],  [&lt;ulink linkID="2012555" linkType="Reference"&gt;2012555&lt;/ulink&gt;], [&lt;ulink linkID="2020807" linkType="Reference"&gt;2020807&lt;/ulink&gt;], [&lt;ulink linkID="2029181" linkType="Reference"&gt;2029181&lt;/ulink&gt;], [&lt;ulink linkID="2137775" linkType="Reference"&gt;2137775&lt;/ulink&gt;], [&lt;ulink linkID="2149815" linkType="Reference"&gt;2149815&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In November 2016, the US FDA granted melatonin Orphan designation for the treatment of Smith-Magenis syndrome in combination with a beta-blocker [&lt;ulink linkID="1870586" linkType="Reference"&gt;1870586&lt;/ulink&gt;]. In January 2017, the FDA granted the drug Orphan designation for the treatment of necrotizing enterocolitis [&lt;ulink linkID="1896111" linkType="Reference"&gt;1896111&lt;/ulink&gt;]. In February 2017, the product was granted Orphan designation for treatment of short bowel syndrome [&lt;ulink linkID="1901651" linkType="Reference"&gt;1901651&lt;/ulink&gt;]. In March 2017, the FDA granted the drug Orphan designation for the treatment of acute acetaminophen overdose [&lt;ulink linkID="1906804" linkType="Reference"&gt;1906804&lt;/ulink&gt;]. In March 2018, the FDA granted melatonin Orphan designation for treatment of perinatal asphyxia [&lt;ulink linkID="2020807" linkType="Reference"&gt;2020807&lt;/ulink&gt;]. Also in March 2018, the FDA granted melatonin Orphan designation for the treatment of subarachnoid hemorrhage [&lt;ulink linkID="2029181" linkType="Reference"&gt;2029181&lt;/ulink&gt;]. In February 2019, melatonin was granted Orphan designation for treatment of hepatocellular carcinoma [&lt;ulink linkID="2137775" linkType="Reference"&gt;2137775&lt;/ulink&gt;]. In April 2019, the FDA awarded melatonin Orphan designation for treatment of heat stroke [&lt;ulink linkID="2149815" linkType="Reference"&gt;2149815&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2016, the EMA's COMP recommended granting melatonin Orphan designations for treatment of neonatal sepsis and treatment of necrotizing enterocolitis [&lt;ulink linkID="1768270" linkType="Reference"&gt;1768270&lt;/ulink&gt;]; in June 2016, the Orphan designation for neonatal sepsis was granted [&lt;ulink linkID="1782604" linkType="Reference"&gt;1782604&lt;/ulink&gt;]; in August 2016, the Orphan designation for necrotizing enterocolitis was granted. In September 2016, the COMP recommended granting melatonin Orphan designation for the treatment of Smith-Magenis syndrome [&lt;ulink linkID="1798089" linkType="Reference"&gt;1798089&lt;/ulink&gt;]; in October 2016, the Orphan designation for Smith-Magenis syndrome was granted [&lt;ulink linkID="1874733" linkType="Reference"&gt;1874733&lt;/ulink&gt;]. In February 2018, the COMP recommended granting melatonin Orphan designation for treatment of neonatal encephalopathy [&lt;ulink linkID="2012555" linkType="Reference"&gt;2012555&lt;/ulink&gt;]; in March 2018, the Orphan designation was granted [&lt;ulink linkID="2028500" linkType="Reference"&gt;2028500&lt;/ulink&gt;]. In September 2018, the COMP recommended granting melatonin Orphan designation for treatment of acute radiation syndrome [&lt;ulink linkID="2079561" linkType="Reference"&gt;2079561&lt;/ulink&gt;]; in October 2018, the Orphan designation was granted [&lt;ulink linkID="2100439" linkType="Reference"&gt;2100439&lt;/ulink&gt;]. In December 2018, the COMP recommended melatonin for Orphan designation for treatment of perinatal asphyxia [&lt;ulink linkID="2105281" linkType="Reference"&gt;2105281&lt;/ulink&gt;]; in January 2019, the Orphan designation was granted [&lt;ulink linkID="2115286" linkType="Reference"&gt;2115286&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2019-02-28T00:00:00.000Z</StatusDate><Source id="2137775" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2168">Short bowel syndrome</Indication><StatusDate>2017-02-16T00:00:00.000Z</StatusDate><Source id="1901651" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3798">Necrotizing enterocolitis</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896111" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2524">Asphyxia</Indication><StatusDate>2018-12-04T00:00:00.000Z</StatusDate><Source id="2105281" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="367">Radiation sickness</Indication><StatusDate>2018-09-11T00:00:00.000Z</StatusDate><Source id="2079561" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="556">Brain disease</Indication><StatusDate>2018-03-13T00:00:00.000Z</StatusDate><Source id="2012555" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3696">Paracetamol overdose</Indication><StatusDate>2017-03-02T00:00:00.000Z</StatusDate><Source id="1906804" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2524">Asphyxia</Indication><StatusDate>2018-03-08T00:00:00.000Z</StatusDate><Source id="2020807" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="609">Genetic disorder</Indication><StatusDate>2016-09-06T00:00:00.000Z</StatusDate><Source id="1798089" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1023">Temperature disorder</Indication><StatusDate>2019-04-22T00:00:00.000Z</StatusDate><Source id="2149815" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="315">Brain hemorrhage</Indication><StatusDate>2018-03-28T00:00:00.000Z</StatusDate><Source id="2029181" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="609">Genetic disorder</Indication><StatusDate>2016-11-03T00:00:00.000Z</StatusDate><Source id="1870586" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3798">Necrotizing enterocolitis</Indication><StatusDate>2016-05-17T00:00:00.000Z</StatusDate><Source id="1768270" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20368">Therapicon Srl</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate>2016-05-17T00:00:00.000Z</StatusDate><Source id="1768270" type="PR"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="US">US</Country><Indication id="1023">Temperature disorder</Indication><AwardedIndication>Treatment of heat stroke</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-04-22T00:00:00.000Z</MileStoneDate><Source id="2149815" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="US">US</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-02-28T00:00:00.000Z</MileStoneDate><Source id="2137775" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="2524">Asphyxia</Indication><AwardedIndication>Treatment of perinatal asphyxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-01-11T00:00:00.000Z</MileStoneDate><Source id="2115286" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="2524">Asphyxia</Indication><AwardedIndication>Treatment of perinatal asphyxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-12-06T00:00:00.000Z</MileStoneDate><Source id="2105281" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="367">Radiation sickness</Indication><AwardedIndication>Treatment of acute radiation syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-10-26T00:00:00.000Z</MileStoneDate><Source id="2100439" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="367">Radiation sickness</Indication><AwardedIndication>Treatment of acute radiation syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-09-13T00:00:00.000Z</MileStoneDate><Source id="2079561" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="US">US</Country><Indication id="315">Brain hemorrhage</Indication><AwardedIndication>Treatment of subarachnoid hemorrhage</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-03-28T00:00:00.000Z</MileStoneDate><Source id="2029181" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="556">Brain disease</Indication><AwardedIndication>Treatment of neonatal encephalopathy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-03-21T00:00:00.000Z</MileStoneDate><Source id="2028500" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="US">US</Country><Indication id="2524">Asphyxia</Indication><AwardedIndication>Treatment of perinatal asphyxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-03-08T00:00:00.000Z</MileStoneDate><Source id="2020807" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="556">Brain disease</Indication><AwardedIndication>Treatment of neonatal encephalopathy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-02-15T00:00:00.000Z</MileStoneDate><Source id="2012555" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="US">US</Country><Indication id="3696">Paracetamol overdose</Indication><AwardedIndication>Treatment of acute acetaminophen overdose</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-03-02T00:00:00.000Z</MileStoneDate><Source id="1906804" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="US">US</Country><Indication id="2168">Short bowel syndrome</Indication><AwardedIndication>Treatment of short bowel syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-02-14T00:00:00.000Z</MileStoneDate><Source id="1901651" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="US">US</Country><Indication id="3798">Necrotizing enterocolitis</Indication><AwardedIndication>Treatment of necrotizing enterocolitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-01-25T00:00:00.000Z</MileStoneDate><Source id="1896111" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="US">US</Country><Indication id="609">Genetic disorder</Indication><AwardedIndication>Treatment of smith-magenis syndrome in combination with a beta-blocker</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-11-03T00:00:00.000Z</MileStoneDate><Source id="1870586" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="609">Genetic disorder</Indication><AwardedIndication>Treatment of Smith-Magenis syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-10-14T00:00:00.000Z</MileStoneDate><Source id="1874733" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="609">Genetic disorder</Indication><AwardedIndication>Treatment of Smith-Magenis syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2016-09-08T00:00:00.000Z</MileStoneDate><Source id="1798089" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="3798">Necrotizing enterocolitis</Indication><AwardedIndication>Treatment of necrotising enterocolitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-08-01T00:00:00.000Z</MileStoneDate><Source id="1798089" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="114">Sepsis</Indication><AwardedIndication>Treatment of neonatal sepsis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-06-27T00:00:00.000Z</MileStoneDate><Source id="1782604" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="3798">Necrotizing enterocolitis</Indication><AwardedIndication>Treatment of necrotising enterocolitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2016-05-19T00:00:00.000Z</MileStoneDate><Source id="1768270" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20368">Therapicon Srl</OwnerCompany><Country id="EU">EU</Country><Indication id="114">Sepsis</Indication><AwardedIndication>Treatment of neonatal sepsis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2016-05-19T00:00:00.000Z</MileStoneDate><Source id="1768270" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2115286" linkType="reference" linkID="2115286"&gt;2115286&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC(=O)NCCc1c[nH]c2c1cc(cc2)OC</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="3170466" number="WO-2016058985" title="Anydrous liquid melatonin composition"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Therapicon Srl" id="20368"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>